These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1591381)

  • 21. The mechanisms of bone lesions in human plasmacytomas.
    Bataille R
    Stem Cells; 1995 Aug; 13 Suppl 2():40-7. PubMed ID: 8520510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mechanisms for formation of myeloma bone disease].
    Yata K; Abe M; Matsumoto T
    Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Myelomatous bone involvement in the man].
    Bataille R; Alexandre C; Chappard D
    Rev Rhum Ed Fr; 1993 Apr; 60(4):261-5. PubMed ID: 8167621
    [No Abstract]   [Full Text] [Related]  

  • 25. Advances in the understanding of myeloma bone disease and tumour growth.
    Yaccoby S
    Br J Haematol; 2010 May; 149(3):311-21. PubMed ID: 20230410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain-derived neurotrophic factor is a potential osteoclast stimulating factor in multiple myeloma.
    Sun CY; Chu ZB; She XM; Zhang L; Chen L; Ai LS; Hu Y
    Int J Cancer; 2012 Feb; 130(4):827-36. PubMed ID: 21400510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New insights in myeloma-induced osteolysis.
    Barillé-Nion S; Bataille R
    Leuk Lymphoma; 2003 Sep; 44(9):1463-7. PubMed ID: 14565645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mutual interaction between myeloma cells and bone marrow microenvironment].
    Abe M
    Rinsho Ketsueki; 2009 Jun; 50(6):453-60. PubMed ID: 19571504
    [No Abstract]   [Full Text] [Related]  

  • 29. Multiple Myeloma and Bone: The Fatal Interaction.
    Marino S; Roodman GD
    Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29229668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.
    Chantry AD; Heath D; Mulivor AW; Pearsall S; Baud'huin M; Coulton L; Evans H; Abdul N; Werner ED; Bouxsein ML; Key ML; Seehra J; Arnett TR; Vanderkerken K; Croucher P
    J Bone Miner Res; 2010 Dec; 25(12):2633-46. PubMed ID: 20533325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
    Giuliani N; Rizzoli V; Roodman GD
    Blood; 2006 Dec; 108(13):3992-6. PubMed ID: 16917004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone disease in multiple myeloma.
    Croucher PI; Apperley JF
    Br J Haematol; 1998 Dec; 103(4):902-10. PubMed ID: 9886299
    [No Abstract]   [Full Text] [Related]  

  • 33. Multiple myeloma: optimal use of salmon calcitonin in the management of myeloma osteoclastic bone disease.
    Bataille R; Tenoudji-Cohen M; Rossi JF
    Br J Haematol; 1983 Jan; 53(1):170-1. PubMed ID: 6848121
    [No Abstract]   [Full Text] [Related]  

  • 34. Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.
    Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
    Curr Drug Targets; 2005 Sep; 6(6):701-11. PubMed ID: 16178802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption.
    Niida S; Kaku M; Amano H; Yoshida H; Kataoka H; Nishikawa S; Tanne K; Maeda N; Nishikawa S; Kodama H
    J Exp Med; 1999 Jul; 190(2):293-8. PubMed ID: 10432291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
    Vallet S; Pozzi S; Patel K; Vaghela N; Fulciniti MT; Veiby P; Hideshima T; Santo L; Cirstea D; Scadden DT; Anderson KC; Raje N
    Leukemia; 2011 Jul; 25(7):1174-81. PubMed ID: 21403648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma.
    Liu H; Liu Z; Du J; He J; Lin P; Amini B; Starbuck MW; Novane N; Shah JJ; Davis RE; Hou J; Gagel RF; Yang J
    Sci Transl Med; 2016 Aug; 8(353):353ra113. PubMed ID: 27559096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple myeloma/hypercalcemia.
    Oyajobi BO
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S4. PubMed ID: 17634143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bone remodeling].
    Cohen-Solal M; de Vernejoul MC
    Therapie; 2003; 58(5):391-3. PubMed ID: 14682185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mechanisms of alveolar bone remodeling].
    Kobayashi Y; Udagawa N
    Clin Calcium; 2007 Feb; 17(2):209-16. PubMed ID: 17272878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.